Brain metastases
Drug research and approvals for brain metastases: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 320 studies of brain metastases are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, and FDA has 3 approved and 7 open orphan designations naming it.
- Recruiting worldwide: 320
- Trials authorized in Canada: 14
- FDA orphan approvals: 3
- EU medicines: 0
- Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing SurgeryNCT07944235 · Not applicable · Fundacion Miguel Servet · starts Sep 30, 2026
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis: A…NCT07935408 · Not reported · Second Affiliated Hospital of Soochow University · starts Mar 1, 2026
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial StenosisNCT07932639 · Phase 4 · Second Affiliated Hospital of Soochow University · starts Mar 21, 2026
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal…NCT07920198 · Not reported · Azienda Ospedaliero-Universitaria di Modena · starts Jul 9, 2026
- Epidural Hydroxyethyl Starch for Post-Dural Puncture Headache in ParturientsNCT07914790 · Not reported · Peking University First Hospital · starts Nov 4, 2026
- Oral Gabapentin Versus Intravenous Neostigmine/Atropine Versus Combination of Both for Prevention of PDPHNCT07916116 · Phase 2 / Phase 3 · Assiut University · starts Mar 1, 2026
- ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain MetastasisNCT07912190 · Not reported · Qian Chu · starts Jan 4, 2026
- Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic…NCT07911449 · Phase 2 · Cho Ray Hospital · starts Feb 27, 2026
- Comparative Effects of Post Isometric Relaxation and Reciprocal Inhibition in Individuals With Cervicogenic Headache.NCT07838545 · Not applicable · Foundation University Islamabad · starts Feb 12, 2026
| Dec 10, 2024 | Evaluating outcome for brain metastases treated with stereotactic radiotherapy with dynamic petFludeoxyglucose (18F) injection | St Josephs Health Centre London | Ongoing |
| Jun 23, 2022 | A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using exablate focused ultrasound during the standard of…Perflutren /pembrolizumab | Insightec | Pending |
| Sep 9, 2021 | A study to evaluate the safety and feasibility of mr-guided focused ultrasound and pembrolizumab treatments for brain metastases in patients with lung cancerDefinity (perflutren) / Pembrolizumab | Insightec | Pending |
| Mar 11, 2021 | Phase III trial of stereotactic radiosurgery (SRS) versus hippocampal-avoidant whole brain radiotherapy (ha-wbrt) for brain metastases from small cell lung…Memantine | Nrg Oncology | Pending |
| Jan 5, 2021 | Phase III trial of salvage stereotactic radiosurgery (SRS) or srs + hippocampal-avoidant whole brain radiotherapy (ha-wbrt) for first or second distant brain…Memantine | Nrg Oncology | Pending |
| Jan 2, 2020 | Differentiating radionecrosis from tumour progression using hybrid flt-pet/MRI in patients with brain metastases treated with stereotactic radiosurgery[18F]-FLT (3'-DEOXY-3'-fluorothymidine) | University Health Network | Ongoing |
| Jan 2, 2020 | An interventional, randomized phase II study investigating the efficacy of immune checkpoint inhibitors while corticosteroid therapy is required for patients…Prednisone / Dexamethasone | Cross Cancer Institute - Cancer Care Alberta | Ongoing |
| May 29, 2019 | A phase 2, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with…Binimetinib (MEK162)/ Encorafenib (LGX818) | Pfizer | Ongoing |
| Apr 27, 2018 | A phase III trial of stereotactic radiosurgery compared with hippocampal-avoidant whole brain radiotherapy (ha-wbrt) plus memantine for 5 or more brain…Memantine | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Ongoing |
| Jan 15, 2018 | A study to evaluate the safety and feasibility of the blood-brain barrier disruption using MRI-guided focused ultrasound in the treatment of HER2-positive…Perflutren | Insightec | Pending |
| Oct 7, 2026 | TukysaIn combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or… | Seattle Genetics, Inc. | Approved |
| Oct 16, 2025 | FerabrightFor magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions… | Azurity Pharmaceuticals, Inc. | Approved |
| Apr 17, 2020 | TucatinibTUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or… | Seattle Genetics, Inc. | Approved |
| Nov 20, 2024 | AzeliragonTreatment of breast cancer brain metastases | Cantex Pharmaceuticals | Designated |
| Mar 25, 2024 | Neratinib maleate TabletsTreatment of HER2-Positive Gastroesophageal Cancer with Brain Metastases | Convalife Pharmaceuticals Co., Ltd. | Designated |
| Mar 21, 2024 | UtideloneTreatment of breast cancer brain metastases | Biostar Pharma, Inc. | Designated |
| Mar 6, 2017 | Fixed dose combination of methimazole and liothyronineTreatment of brain metastases in patients with primary lung cancer | Musli Thyropeutics Ltd. | Designated |
| Apr 15, 2015 | [α′N-(2′succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg…Treatment of breast cancer patients with brain metastases | Angiochem, Inc. | Designated |
| Jul 28, 2004 | EfaproxiralAdjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer | Allos Therapeutics, Inc. | Designated |
| Jan 27, 2003 | Motexafin gadoliniumFor use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors | Pharmacyclics, LLC | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA